The role of a single-dose of intraoperative methadone on postoperative pain and opioid consumption in patients undergoing hysterectomy remains scarcely explored. A prospective double-blind, randomised controlled trial investigating the effect of a single-dose of intraoperative methadone in patients scheduled for same day hysterectomy is therefore conducted.
Background with aim: Hysterectomy is the most common major gynaecological procedure in the world and hysterectomy on benign indications are increasingly being performed as same-day surgery. Therefore, perioperative anaesthesia has moved towards the use of very short-acting opioids with the incitement to speed up extubation and facilitate hospital discharge. However, the potential consequence is that more patients experience pain and discomfort. Methadone has several desirable pharmacological features, and a single intraoperative dose of the long acting opioid could therefore theoretically expand the analgesic window and reduce postoperative opioid consumption compared to the more conventional use of short-acting opioids. The aim of this study is to investigate the effect of a single-dose of intravenous intraoperative methadone on postoperative opioid consumption, pain and side effects in patients scheduled for hysterectomy for benign indications. Our primary hypothesis is that intravenous perioperative methadone reduces opioid consumption (oral cumulative equivalent dose) by 30% during the first 24 postoperative hours compared to intravenous morphine. Methods: 126 patients will be included in an investigator-initiated, prospective, randomised, double-blind, controlled trial with two arms: an intervention arm (methadone 0.2 mg/kg ideal body weight) and a control arm (morphine 0.2 mg/kg ideal body weight). The study will be GCP-monitored, and is approved by the Danish Health and Medicines Authority (2018-004351-20) and the Central Denmark Region Committees on Health Research Ethics (1-10-72-365-18). Hypothesis: The results will probably be applicable to other types of surgery involving visceral pain, and thus the present study has the potential to improve the pain management for a large number of patients undergoing surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
126
Department of Anaesthesiology and Intensive Care, Horsens Regional Hospital
Horsens, Central Jutland, Denmark
Opioid consumption at 24 hours after extubation (cumulative opioid consumption)
cumulative opioid consumption in oral morphine equivalents
Time frame: 24 hours
Opioid consumption at 6 hours after extubation (cumulative opioid consumption)
cumulative opioid consumption in oral morphine equivalents
Time frame: 6 hours
Pain intensity (NRS, 0-10) at rest and coughing
Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain)
Time frame: 0-48 hours after extubation
Postoperative side effects/ adverse events (nausea and vomiting, sedation, hypoventilation, and hypoxemia)
Number of patients
Time frame: 0-72 hours after extubation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.